Quantcast

Latest Idenix Pharmaceuticals Inc. Stories

2010-01-04 15:05:00

CAMBRIDGE, Mass., Jan. 4 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX) announced today that management will present a corporate overview at the upcoming 28(th) Annual J. P. Morgan Healthcare Conference on Thursday, January 14, 2010 at 8:00 a.m. PT at the Westin St. Francis Hotel in San Francisco. The live and archived webcast of the company presentation can be accessed under "Calendar of Events" in the Idenix Investor Center at www.idenix.com. Please log in...

2009-11-03 07:00:00

CAMBRIDGE, Mass., Nov. 3 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, announced today that it has initiated a Phase II clinical trial evaluating IDX184, a liver-targeted nucleotide prodrug candidate for the treatment of HCV, in combination with pegylated interferon and ribavirin, in treatment-naive hepatitis C genotype 1-infected patients....

2009-10-30 07:00:00

CAMBRIDGE, Mass., Oct. 30 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced presentations of data on IDX184, a once-daily novel liver-targeted nucleotide prodrug of 2'-methyl guanosine (2'MeG) for the treatment of HCV, at the annual meeting of the American Association for the Study of Liver Diseases (AASLD) currently being held in...

2009-10-29 15:05:00

CAMBRIDGE, Mass., Oct. 29 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that Novartis Pharma AG has decided not to exercise its option to license IDX184, a novel liver-targeted prodrug of 2'-methyl guanosine nucleotide, for the treatment of HCV. As a result, Idenix retains the worldwide rights to develop, commercialize and license...

2009-10-29 15:05:00

CAMBRIDGE, Mass., Oct. 29 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today reported unaudited financial results for the third quarter and nine months ended September 30, 2009. At September 30, 2009, Idenix's cash, cash equivalents and marketable securities totaled $61.1 million. Business Highlights Idenix successfully completed a...

2009-10-27 15:05:00

CAMBRIDGE, Mass., Oct. 27 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX) announced today that management will present a corporate overview at the upcoming Oppenheimer 20(th) Annual Healthcare Conference on Tuesday, November 3rd, 2009 at 2:45 p.m. ET at the Waldorf Astoria, New York. The live and archived webcast of the company presentation can be accessed under "Calendar of Events" in the Idenix Investor Center at www.idenix.com. Please log in approximately 5-10...

2009-10-22 15:05:00

CAMBRIDGE, Mass., Oct. 22 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc., (Nasdaq: IDIX) announced today that it will report its financial results for the third quarter of 2009 on Thursday, October 29, 2009 after U.S. financial markets close. In conjunction with the issuance of the press release, Idenix management will host a conference call at 4:30 p.m. ET on Thursday, October 29, 2009 to discuss the company's financial results for the third quarter of 2009 and provide an update...

2009-10-01 15:05:00

CAMBRIDGE, Mass., Oct. 1 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that two abstracts on IDX184, the company's lead hepatitis C development program, have been accepted for presentation at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD, October 30-November 3, 2009 in Boston,...

2009-09-28 15:05:00

CAMBRIDGE, Mass., Sept. 28 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX) announced today that management will present a corporate overview at the upcoming JMP Securities Healthcare Focus Conference on Monday, October 5, 2009 at 8:30 a.m. ET at The New York Palace Hotel. The live and archived webcast of the company presentation can be accessed under "Calendar of Events" in the Idenix Investor Center at www.idenix.com. Please log in approximately 5-10 minutes before...

2009-07-20 15:05:00

CAMBRIDGE, Mass., July 20 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that it has successfully completed a three-day proof-of-concept study of IDX184. Idenix is developing IDX184, a novel liver-targeted prodrug of 2'-methyl guanosine nucleotide, for the treatment of HCV. This double-blind, placebo-controlled, monotherapy,...


Word of the Day
vermicular
  • Like a worm in form or movement; vermiform; tortuous or sinuous; also, writhing or wriggling.
  • Like the track or trace of a worm; appearing as if worm-eaten; vermiculate.
  • Marked with fine, close-set, wavy or tortuous lines of color; vermiculated.
  • A form of rusticated masonry which is so wrought as to appear thickly indented with worm-tracks.
This word ultimately comes from the Latin 'vermis,' worm.
Related